SCYNEXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.03 USD | +1.00% |
|
+7.98% | -8.97% |
| 08/05 | Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M | MT |
| 08/05 | SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chart calendar SCYNEXIS, Inc.
6507c25f3dfbc80d2d92530704.OcNup97YlYFhN0s5b8jXlj-E3FjniAINzAz3s0bGVuA.UaEiwJO7wcAVdgcNDam09AuwnR2U3jZq-0ONnneHPYMO8yLIkKChuTZoLA~ab773507f1008273d0294a6bd477b7f9
Upcoming events on SCYNEXIS, Inc.
Past events on SCYNEXIS, Inc.
| 19/06/2024 07:00 pm | Annual General Meeting |
| 10/05/2024 02:00 am | Q1 2024 Earnings Release |
| 29/04/2024 03:30 pm | Clinical Microbiology and Infectious Diseases European Congress - Poster Number P2935 |
| 29/04/2024 03:30 pm | Clinical Microbiology and Infectious Diseases European Congress - Mahmoud Ghannoum, Ph.D |
| 28/04/2024 05:00 pm | Clinical Microbiology and Infectious Diseases European Congress |
| 29/03/2024 01:31 am | Q4 2023 Earnings Release |
| 07/02/2024 09:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 25/01/2024 | Advances Against Aspergillosis and Mucormycosis Conference |
| 14/11/2023 03:47 am | Q3 2023 Earnings Release |
| 21/10/2023 06:05 pm | Trends in Medical Mycology Congress - Abstract Number: S08.6 |
| 28/09/2023 11:20 pm | Cantor Global Healthcare Conference |
| 12/09/2023 06:30 pm | H.C. Wainwright Global Investment Conference |
| 15/08/2023 02:00 am | Q2 2023 Earnings Release |
| 20/06/2023 10:00 pm | Maxim Group Virtual Healthcare Conference |
| 14/06/2023 07:00 pm | Annual General Meeting |
| 11/05/2023 04:30 pm | Q1 2023 Earnings Release |
| 18/04/2023 03:30 pm | European Congress of Clinical Microbiology and Infectious Diseases - P3402 |
| 16/04/2023 05:18 pm | European Congress of Clinical Microbiology and Infectious Diseases |
| 16/04/2023 03:30 pm | European Congress of Clinical Microbiology and Infectious Diseases - P2047 |
| 16/04/2023 03:30 pm | European Congress of Clinical Microbiology and Infectious Diseases - P2068 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,12 0,13 -9.82% | 0,00 0,00 - | 13,2 13,9 -5.24% | 5,09 4,91 3.65% | 140 142 -1.3% | 25,1 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -51,0 -47,0 -8.59% | 0,00 0,00 - | -85,2 -78,7 -8.2% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -48,9 -47,2 -3.7% | -51,1 -47,5 -7.59% | -60,8 -59,8 -1.67% | -85,8 -81,6 -5.14% | 72,7 91,9 -20.93% | -18,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -53,7 -52,0 -3.27% | -58,3 -31,9 -83.08% | -36,0 -29,1 -23.69% | -67,5 -71,3 5.38% | 67,2 83,5 -19.57% | -8,74 |
|
Net income Million USD | Released Forecast Spread | -53,7 -51,9 -3.57% | -55,2 -26,0 -112.08% | -32,9 -26,9 -22.21% | -62,8 -66,6 5.76% | 67,0 83,5 -19.73% | -8,97 |
|
EPS USD | Released Forecast Spread | -9,60 -8,62 -11.41% | -5,15 -1,76 -193.33% | -1,25 -0,99 -26.69% | -1,47 -1,54 4.55% | 1,39 1,53 -8.91% | -0,22 |
| Announcement Date | 11/03/20 | 29/03/21 | 29/03/22 | 31/03/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,69 1,09 -37.18% | 1,32 1,64 -19.44% | 1,56 2,06 -24.57% | 1,52 1,36 11.96% | 1,13 0,97 16.35% | 131 95,4 37.79% | 1,76 5,89 -70.08% | 5,80 7,65 -24.2% | 1,37 0,30 353.14% | 2,27 | 13,2 | 8,50 | 0,86 | 8,40 |
|
EBIT Million USD | Released Forecast Spread | -19,7 -21,3 7.2% | -21,7 -20,0 -8.65% | -21,8 -21,1 -3.47% | -22,5 -18,3 -23.01% | -10,7 -12,1 11.8% | 117 83,5 39.53% | -10,1 -6,95 -45.3% | -23,1 -3,85 -499.4% | -9,51 -9,79 2.91% | -8,28 | 2,53 | -2,55 | -8,54 | -1,09 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -10,2 -22,0 53.91% | -13,3 -21,4 37.49% | -29,6 -22,0 -34.56% | -14,4 -19,3 25.17% | -33,9 -12,9 -161.83% | 122 83,1 47.13% | -1,76 -7,05 75.09% | -19,4 -3,45 -464.49% | 0,94 -9,41 110.01% | -7,89 | 2,88 | -2,31 | -7,90 | -0,50 |
|
Net income Million USD | Released Forecast Spread | -5,45 -22,4 75.66% | -13,3 -21,2 37.03% | -29,6 -22,1 -34.05% | -14,4 -19,3 25.17% | -33,9 -12,9 -161.83% | 122 79,8 53.22% | -1,76 -7,05 75.09% | -19,6 -3,45 -468.49% | 0,41 -9,41 104.37% | -7,89 | 2,88 | -2,31 | -7,90 | -0,50 |
|
EPS USD | Released Forecast Spread | -0,17 -0,75 77.41% | -0,31 -0,59 47.1% | -0,62 -0,50 -24.42% | -0,29 -0,40 28.1% | -0,71 -0,27 -161.03% | 2,46 1,45 69.42% | -0,04 -0,15 72.6% | -0,39 -0,07 -437.93% | 0,01 -0,19 105.15% | -0,16 | 0,02 | -0,06 | -0,16 | -0,04 |
| Announcement Date | 12/05/22 | 15/08/22 | 09/11/22 | 31/03/23 | 10/05/23 | 14/08/23 | 13/11/23 | 28/03/24 | 08/05/24 | - | - | - | - | - |
More events
Past sector events for SCYNEXIS, Inc.
| 21/06/2024 08:58 pm | DEVA HOLDING: Q1 2024 Earnings Release |
| 14/06/2024 02:51 am | EIS ECZACIBASI ILAÇ, SINAI VE FINANSAL YATIRIMLAR SANAYI VE TICARET: Q1 2024 Earnings Release |
| 11/06/2024 11:00 am | BORA PHARMACEUTICALS CO., LTD.: June 2024 Sales and Revenue Release |
| 07/06/2024 04:03 pm | SCINOPHARM TAIWAN, LTD.: May 2024 Sales and Revenue Release |
| 07/06/2024 02:47 pm | LOTUS PHARMACEUTICAL CO., LTD.: May 2024 Sales and Revenue Release |
| 30/05/2024 05:38 pm | SUVEN PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 30/05/2024 04:30 pm | ROIVANT SCIENCES LTD.: Q4 2023 Earnings Release |
| 30/05/2024 11:54 am | MARKSANS PHARMA LIMITED: Q4 2024 Earnings Release |
| 29/05/2024 05:30 pm | FDC LIMITED: Q4 2024 Earnings Release |
| 29/05/2024 02:56 pm | JUBILANT PHARMOVA LIMITED: Q4 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SCYX Stock
- Calendar SCYNEXIS, Inc.
